These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16968122)

  • 1. Is DOTS-plus a feasible and cost-effective strategy?
    Garner P; Alejandria M; Lansang MA
    PLoS Med; 2006 Sep; 3(9):e350. PubMed ID: 16968122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa.
    Wilton P; Smith RD; Coast J; Millar M; Karcher A
    Int J Tuberc Lung Dis; 2001 Dec; 5(12):1137-42. PubMed ID: 11769772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug-resistant TB in the Philippines: totem and taboo.
    Portero JL; Rubio M
    PLoS Med; 2006 Dec; 3(12):e539; author reply e549. PubMed ID: 17194204
    [No Abstract]   [Full Text] [Related]  

  • 4. Reforming tuberculosis control in Ukraine: results of pilot projects and implications for the national scale-up of DOTS.
    Vassall A; Chechulin Y; Raykhert I; Osalenko N; Svetlichnaya S; Kovalyova A; van der Werf MJ; Turchenko LV; Hasker E; Miskinis K; Veen J; Zaleskis R
    Health Policy Plan; 2009 Jan; 24(1):55-62. PubMed ID: 19056804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines.
    Tupasi TE; Gupta R; Quelapio MI; Orillaza RB; Mira NR; Mangubat NV; Belen V; Arnisto N; Macalintal L; Arabit M; Lagahid JY; Espinal M; Floyd K
    PLoS Med; 2006 Sep; 3(9):e352. PubMed ID: 16968123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological and cost analysis of multidrug-resistant tuberculosis in Oman.
    Mohammadi A; Nassor ZS; Behlim T; Mohammadi E; Govindarajan R; Al Maniri A; Smego RA
    East Mediterr Health J; 2008; 14(6):1240-5. PubMed ID: 19161099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador.
    Rouzier VA; Oxlade O; Verduga R; Gresely L; Menzies D
    Int J Tuberc Lung Dis; 2010 Oct; 14(10):1316-22. PubMed ID: 20843424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-drug resistant tuberculosis in context of RNTCP.
    Arora VK; Visalakshi P
    Indian J Chest Dis Allied Sci; 2003; 45(3):215-9. PubMed ID: 12866642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOTS plus strategy in resource-poor countries.
    Ollé-Goig JE
    Int J Tuberc Lung Dis; 1999 Sep; 3(9):843; author reply 844. PubMed ID: 10488895
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of multidrug-resistant tuberculosis: Update 2007.
    Yew WW; Leung CC
    Respirology; 2008 Jan; 13(1):21-46. PubMed ID: 18197909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DOTS strategy for controlling the global tuberculosis epidemic.
    Frieden TR; Munsiff SS
    Clin Chest Med; 2005 Jun; 26(2):197-205, v. PubMed ID: 15837105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of DOTS in urban Brazil.
    Mohan CI; Bishai D; Cavalcante S; Chaisson RE
    Int J Tuberc Lung Dis; 2007 Jan; 11(1):27-32. PubMed ID: 17217126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOTS plus strategy in resource-poor countries.
    Davies PD
    Int J Tuberc Lung Dis; 1999 Sep; 3(9):843-4. PubMed ID: 10488896
    [No Abstract]   [Full Text] [Related]  

  • 14. Southern Africa is moving swiftly to combat the threat of XDR-TB.
    Wise J
    Bull World Health Organ; 2006 Dec; 84(12):924-5. PubMed ID: 17242824
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effective control of drug-resistant TB: listening to other voices.
    Portero JL; Rubio M
    PLoS Med; 2006 Dec; 3(12):e542. PubMed ID: 17194207
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive cost description of tuberculosis care.
    Weis SE; Miller TL; Hilsenrath PE; Moonan PK
    Int J Tuberc Lung Dis; 2005 Apr; 9(4):467-8; author reply 468-9. PubMed ID: 15830756
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis.
    Sterling TR; Lehmann HP; Frieden TR
    BMJ; 2003 Mar; 326(7389):574. PubMed ID: 12637401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro drug resistance and response to therapy in pulmonary tuberculosis patients under a DOTS programme in south India.
    Aparna SB; Reddy VC; Gokhale S; Moorthy KV
    Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):564-70. PubMed ID: 19243801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Some topics of TB research using epidemetric models].
    Mori T; Uchimura K
    Kekkaku; 2008 Dec; 83(12):803-9. PubMed ID: 19172826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of DOTS and DOTS-plus on multidrug resistant TB: DOTS-plus strengthens, not weakens, DOTS programmes.
    Nardell EA
    BMJ; 2003 Jul; 327(7407):164; author reply 164. PubMed ID: 12869471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.